IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i15p9196-d873649.html
   My bibliography  Save this article

Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis

Author

Listed:
  • Yeo Jin Choi

    (Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea
    Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul 02447, Korea)

  • Chang-Young Choi

    (Department of Internal Medicine, Ajou University Medical Center, Suwon 16499, Korea)

  • Sandy Jeong Rhie

    (Graduate School of Converging Clinical & Public Health, Ewha Womans University, Seoul 03670, Korea
    Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Korea)

  • Sooyoung Shin

    (Department of Pharmacy, College of Pharmacy, Ajou University, Suwon 16499, Korea)

Abstract

Despite substantially elevated risk of serious adverse events (SAEs) from targeted therapy in combination with chemotherapy, comprehensive pharmacovigilance research is limited. This study aims to systematically assess SAE risks of commonly prescribed targeted agents (bevacizumab, cetuximab, and panitumumab) in patients with rat sarcoma viral oncogene homolog (RAS) wild-type metastatic colon cancer. Keyword searches of Cochrane Library, Clinical Key and MEDLINE were conducted per PRISMA-NMA guidelines. Frequentist network meta-analysis was performed with eight randomized controlled trials to compare relative risk (RR) of 21 SAE profiles. The risks of hematological, gastrointestinal, neurological SAE were insignificant among targeted agents ( p > 0.05). The risk of serious hypertension was substantially elevated in bevacizumab-based chemotherapy ( p < 0.05), whereas panitumumab-based chemotherapy had markedly elevated risk of serious thromboembolism (RR 3.65; 95% CI 1.30–10.26). Although both cetuximab and panitumumab demonstrated increased risk of serious dermatological and renal toxicities, panitumumab-based chemotherapy has relatively higher risk of skin toxicity (RR 15.22; 95% CI 7.17–32.35), mucositis (RR 3.18; 95% CI 1.52–6.65), hypomagnesemia (RR 20.10; 95% CI 5.92–68.21), and dehydration (RR 2.81; 95% CI 1.03–7.67) than cetuximab-based chemotherapy. Thus, further studies on risk stratification and SAE management are warranted for safe administration of targeted agents.

Suggested Citation

  • Yeo Jin Choi & Chang-Young Choi & Sandy Jeong Rhie & Sooyoung Shin, 2022. "Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis," IJERPH, MDPI, vol. 19(15), pages 1-18, July.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:15:p:9196-:d:873649
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/15/9196/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/15/9196/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:15:p:9196-:d:873649. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.